ERYP.PA - ERYTECH Pharma S.A.

Paris - Paris Delayed Price. Currency in EUR
9.475
-0.065 (-0.68%)
As of 3:15PM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close9.540
Open9.600
Bid20.400 x 400
Ask21.040 x 4700
Day's Range9.370 - 9.600
52 Week Range9.020 - 29.700
Volume11,963
Avg. Volume46,896
Market Cap169.958M
Beta1.73
PE Ratio (TTM)N/A
EPS (TTM)-2.950
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.24
  • GlobeNewswire5 days ago

    Monthly information related to total number of voting rights and shares composing the share capital - June 30, 2018

    Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France   ERN France, July 12, 2018 (GLOBE NEWSWIRE) --  Monthly information related to total number of voting rights ...

  • Benzinga21 days ago

    Benzinga's Daily Biotech Pulse: Epidiolex, Roche's Influenza Drug Gets Priority Review Status, Xeris Jumps On Positive Trial Results

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 25) Quest Diagnostics Inc (NYSE: DGX )(Barclays upgraded shares ...

  • GlobeNewswire23 days ago

    ERYTECH Confirms Strategic Focus of Eryaspase on Solid Tumors and Ceases Development in Acute Lymphoblastic Leukemia

    Confirms planned launch of company-sponsored randomized Phase 2 trial in first-line pancreatic cancer, in addition to ongoing launch of Phase 3 trial in second-line pancreatic cancer. LYON, France and CAMBRIDGE Mass., June 24, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (ERYP.PA) (ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will focus its development efforts for its product candidate eryaspase on the potential treatment of selected solid tumor indications.

  • GlobeNewswire23 days ago

    ERYTECH Confirms Strategic Focus of Eryaspase on Solid Tumors and Ceases Development in Acute Lymphoblastic Leukemia

    Confirms planned launch of company-sponsored randomized Phase 2 trial in first-line pancreatic cancer, in addition to ongoing launch of Phase 3 trial in second-line pancreatic cancer. LYON, France and CAMBRIDGE Mass., June 24, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (ERYP) (ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will focus its development efforts for its product candidate eryaspase on the potential treatment of selected solid tumor indications.

  • GlobeNewswire27 days ago

    ERYTECH to Present at JMP Securities Life Science Conference

    LYON, France, June 20, 2018 (GLOBE NEWSWIRE) --  ERYTECH Pharma  (Euronext Paris:ERYP) (Nasdaq:ERYP) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic ...

  • GlobeNewswire27 days ago

    ERYTECH to Present at JMP Securities Life Science Conference

    LYON, France, June 20, 2018-- ERYTECH Pharma, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced ...

  • GlobeNewswirelast month

    ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018

    LYON, France, June 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (ERYP.PA) (ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present preclinical data on the enzymatic activity of eryaspase (GRASPA®) for the treatment of relapsed acute lymphoblastic leukemia (ALL) and results of its Phase 2b clinical trial evaluating eryaspase (GRASPA®) for the treatment of acute myeloid leukemia (AML) at the European Hematology Association (EHA) Congress, being held June 14-17, 2018 in Stockholm, Sweden. The preclinical eryaspase data will be presented during Poster Session I by Dr. Karine Aguera, ERYTECH`s R&D Project Leader.

  • GlobeNewswirelast month

    ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018

    ERYTECH Pharma (ERYP) (ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present preclinical data on the enzymatic activity of eryaspase (GRASPA®) for the treatment of relapsed acute lymphoblastic leukemia (ALL) and results of its Phase 2b clinical trial evaluating eryaspase (GRASPA®) for the treatment of acute myeloid leukemia (AML) at the European Hematology Association (EHA) Congress, being held June 14-17, 2018 in Stockholm, Sweden. The preclinical eryaspase data will be presented during Poster Session I by Dr. Karine Aguera, ERYTECH’s R&D Project Leader.

  • GlobeNewswirelast month

    Erytech Pharma S.A. : General Meeting to be held on June 28, 2018 and Availability of Related Materials

    LYON, France, June  07, 2018  (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP) , a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer ...

  • GlobeNewswirelast month

    General Meeting to be held on June 28, 2018 and Availability of Related Materials

    LYON, France, June 07, 2018-- ERYTECH Pharma, a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS ...

  • GlobeNewswirelast month

    Monthly information related to total number of voting rights and shares composing the share capital -May 31, 2018

    Article 223-16 of general regulation of French Autorité des Marchés Financiers ERN France, June 06, 2018 (GLOBE NEWSWIRE) --  Monthly information related to total number of voting rights and shares composing ...

  • GlobeNewswirelast month

    ERYTECH to Present Pharmacodynamic Data from Phase 2/3 Trial of Eryaspase in ALL at ASCO 2018

    LYON, France, June 04, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (ERYP.PA) (ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present pharmacodynamic characterization data from its Phase 2/3 trial of eryaspase (GRASPA®) in combination with chemotherapy for the treatment of relapsed acute lymphoblastic leukemia (ALL) at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 1-5, 2018 in Chicago, Illinois. Poster Session: Pharmacodynamic Characterization of eryaspase (L-asparaginase Encapsulated in Red Blood Cells) in Combination with Chemotherapy in a Phase 2/3 Trial in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517).

  • GlobeNewswirelast month

    ERYTECH to Present Pharmacodynamic Data from Phase 2/3 Trial of Eryaspase in ALL at ASCO 2018

    ERYTECH Pharma (ERYP) (ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present pharmacodynamic characterization data from its Phase 2/3 trial of eryaspase (GRASPA®) in combination with chemotherapy for the treatment of relapsed acute lymphoblastic leukemia (ALL) at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 1-5, 2018 in Chicago, Illinois. Poster Session: Pharmacodynamic Characterization of eryaspase (L-asparaginase Encapsulated in Red Blood Cells) in Combination with Chemotherapy in a Phase 2/3 Trial in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517).

  • GlobeNewswire2 months ago

    ERYTECH to Webcast Presentation at the Jefferies Global Healthcare Conference

    LYON, France, May 30, 2018-- ERYTECH Pharma, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced ...

  • GlobeNewswire2 months ago

    ERYTECH Reports First Quarter 2018 Financial Results and Provides Business Update

    ERYTECH Pharma (ERYP) (ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business update and reported its financial results for the quarter ended March 31, 2018. “Following our successful Nasdaq listing at the end of last year, the first quarter of this year has been focused on the execution of the plan to advance our pipeline into solid tumor indications,” said Gil Beyen, chief executive officer at ERYTECH.

  • Business Wire2 months ago

    ERYTECH Reports First Quarter 2018 Financial Results and Provides Business Update

    ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business update and reported its financial results for the quarter ended March 31, 2018. “Set up activities are on track for the launch of a pivotal Phase 3 trial in second line pancreatic cancer and a Phase 2 trial in first line triple-negative breast cancer. Feedback was obtained from the Commission for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) on the design of the proposed Phase 3 trial with eryaspase in second line pancreatic cancer, confirming earlier feedback by the U.S. Food and Drug Administration (FDA).

  • Business Wire2 months ago

    ERYTECH Strengthens Executive Team with the Appointment of Alex Dusek as VP of Commercial Strategy

    ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it has appointed Alex Dusek as its Vice President Commercial Strategy and member of the executive team. “I am pleased to welcome Alex to the ERYTECH team at this exciting juncture,” said Gil Beyen, Chairman and CEO of ERYTECH.

  • GlobeNewswire2 months ago

    ERYTECH Strengthens Executive Team with the Appointment of Alex Dusek as VP of Commercial Strategy

    ERYTECH Pharma (ERYP) (ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it has appointed Alex Dusek as its Vice President Commercial Strategy and member of the executive team. “I am pleased to welcome Alex to the ERYTECH team at this exciting juncture,” said Gil Beyen, Chairman and CEO of ERYTECH. Prior to joining ERYTECH, Mr. Dusek served as the Vice President of Commercial Strategy at Argos Therapeutics, a publicly traded immuno-oncology company, where his work included pre-launch planning for the commercial distribution of an advanced cell therapy product.

  • GlobeNewswire2 months ago

    ERYTECH to Host First Quarter 2018 Conference Call and Business Update

    LYON, France, May 09, 2018-- ERYTECH Pharma, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced ...